A first-of-its-kind congressional committee hearing took place on Thursday, with lawmakers examining the impacts of Food and Drug Administration (FDA) inaction on developing regulations to allow for the sale of hemp-derived CBD as food items or dietary supplements.
The House Oversight and Accountability Subcommittee on Health Care and Financial Services announced the scheduling of the hearing—titled “Hemp in the Modern World: The Years long Wait for FDA Action”—last week.
“FDA announced earlier this year that it’s needs a new regulatory framework for hemp and CBD,” Chairwoman Lisa McClain (R-MI) said in her opening remarks. “Translation: Give us more authority. Give us more money. Give us more staff and only then will we actually do our duties under the law.”
“This announcement has led to confusion and uncertainty in the market, which has suppressed the ability for good faith manufacturers to sell CBD products,” she said. “It only benefits bad actors who capitalize on the confusion and the flood of the market with potentially unsafe products. The FDA must do better and use their already existing authority to regulate how derived products you know actually do the job they were signed up to do.”
“But instead of regulating hemp-derived products
Read full article on Marijuana Moment
